Please select a headline from the list below to view full details.


Wednesday 5 April 2006
Last month, six volunteers taking part in a phase I clinical trial of a monoclonal antibody, TGN1412, experienced severe adverse events. As part of the Academy of Medical Sciences’ on-going work into the research and development of new medicines, a small working group was convened to discuss some of the broad questions and issues arising from the TGN1412 trial.
Follow us: